Related Experiment Videos
[ACE inhibition: mechanisms of cardioprotection in chronic experimental heart failure]
1Medizinische Universitätsklinik Würzburg.
Insights
Early captopril treatment in heart failure animal models improved hemodynamics and reduced fluid retention. This renin-angiotensin-aldosterone system inhibition shows promise for preventing symptoms in ventricular dysfunction.
Area of Science:
- Cardiovascular Physiology
- Pharmacology
Context:
- Chronic heart failure models in dogs and rats are crucial for understanding disease progression.
- Rapid ventricular pacing and myocardial infarction are established methods to induce heart failure phenotypes.
Purpose:
- To investigate the effects of early captopril administration on hemodynamic and neurohumoral mechanisms in animal models of heart failure.
- To assess the long-term impact of ACE inhibition on survival and disease progression.
Summary:
- Captopril therapy in dogs with pacing-induced heart failure prevented increased peripheral vascular resistance, reduced cardiac output decline, and lowered pulmonary arterial pressure.
- ACE inhibition significantly decreased aldosterone secretion, attenuated sympathetic activity, and prevented inappropriate vasopressin release, leading to reduced symptoms and fluid retention.
- Similar benefits, including improved hemodynamics, cardiac size, and survival, were observed in rats with myocardial infarction treated with captopril.
Impact:
- Early inhibition of the renin-angiotensin-aldosterone system with captopril demonstrates significant therapeutic potential in managing heart failure.
- This approach may offer a preventative strategy for patients with ventricular dysfunction, even before the onset of clinical symptoms.
Abstract:
In 1984 we demonstrated in an animal model of chronic congestive heart failure due to rapid right ventricular pacing in chronically instrumented dogs, that the inhibition of the renin-angiotensin-aldosterone system by captopril from the onset of pacing has beneficial effects on hemodynamic and neurohumoral mechanisms. In contrast to control animals, dogs on a chronic therapy with the ACE-inhibitor showed no significant increase in peripheral vascular resistance, a reduced decline of cardiac output and no significant increase of mean pulmonary arterial pressure. Chronic ACE-inhibition led to a significant reduction of the secretion of aldosterone, to an attenuation of the activation of the sympathetic activity and to a prevention of inappropriate stimulation of vasopressin secretion. This was associated with a reduction in symptoms and a lack of fluid retention, whereas control animals developed pleural infusions and ascites. Similar beneficial effects have been demonstrated in rats following myocardial infarction during a long-term therapy with captopril on hemodynamic parameters, heart size, and survival. Thus, early inhibition of the renin-angiotensin-aldosterone system in heart failure may be an attractive approach for treatment in patients with ventricular dysfunction even before symptoms develop.